Shanaka Anslem Perera ⚡(@shanaka86):Moderna $MRNA shares surged dramatically after positive Phase 3 results for its personalized mRNA vaccine intismeran combined with Merck’s Keytruda, extending recurrence-free and distant metastasis-free survival in high-risk melanoma patients post-surgery. The treatment targets neoantigens from each patient’s tumor to train the immune system against cancer return, marking the first successful late-stage trial for an individualized mRNA cancer therapy rather than a broad preventive. The announcement drove massive market cap gains for Moderna, highlighting renewed investor optimism in mRNA applications beyond COVID vaccines and potential expansion to other cancers like lung and bladder.

2026.08.20 01:13

Moderna $MRNA shares surged dramatically after positive Phase 3 results for its personalized mRNA vaccine intismeran combined with Merck’s Keytruda, extending recurrence-free and distant metastasis-free survival in high-risk melanoma patients post-surgery. The treatment targets neoantigens from each patient’s tumor to train the immune system against cancer return, marking the first successful late-stage trial for an individualized mRNA cancer therapy rather than a broad preventive. The announcement drove massive market cap gains for Moderna, highlighting renewed investor optimism in mRNA applications beyond COVID vaccines and potential expansion to other cancers like lung and bladder.